The contemporaneous administration of OXA and CLANs IDO1 could achieve synergetic antitumor effects via promoting DC maturation, increasing tumor-infiltrating T lymphocytes as well as decreasing the number of regulatory T cells in a subcutaneous colorectal tumor model. Here, IDO1 is linked to neoplasm.